Abstract

Introduction: Overweight and obesity is one of the great global pandemics; its liver disease is fatty liver, which could progress to chronic liver disease such as cirrhosis and hepatocarcinoma; hence the importance of its prevalence, and high impact on Ecuadorian morbidity and mortality.

Objective: To determine the prevalence of NAFLD, related to overweight in outpatients of the Metropolitan Hospital of Quito, in a period of 6 months.

Methodology: A cross-period analytical epidemiological study was carried out in outpatients who attend the Metropolitan Hospital of Quito under the modality of a medical check-up.

 Results: The prevalence of fatty liver according to sonography was 37%. When comparing nutritional status and fatty liver, the overweight and obesity group had 51.7%; according to age in > 50 years they predominate with 44.4%; by gender, men stand out with 74%; and in relation to physical exercise, the patients who performed did not present fatty liver with 67.2%.

Conclusion: It is concluded that there is a high prevalence of NAFLD related to overweight and obesity, predominantly in the male gender; In addition, as age advances, they are prone to acquire this liver disease. NAFLD can be evaluated in the majority of patients with high sensitivity and specificity through hepatic sonography and the INDEX biochemical test. (HSI); An adequate healthy lifestyle that includes physical activity (exercise) reduces the risk of suffering from non-alcoholic fatty liver.

Keywords: Obesity; Nonalcoholic Fatty Liver Disease (NAFLD); Hepatic Echosonography (Ultrasound); Hepatic Steatosis Index (HSI); Transaminases; Steatohepatitis; Cirrhosis; Hepatocarcinoma

References

1. Watanabe S., et al. “Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis” (2014): 1-14.
2. Feldman M., et al. “Gastrointestinal an liver disease”. Edition: 10^th Barcelona: ELSEVIER (2016): 87.
3. Bedogni G., et al. “Epidemiology of fatty liver: An update”. World Journal of Gastroenterology (2014): 9050-9054.
4. Santos L., et al. “Non alcoholic fatty liver disease. The new millennium pandemia”. Asoc Colomb Gastroenterol Endosc Dig Coloproctol Hepatol (2010): 373-391.
5. Farreras P and Rozman C. “Enfermedades del aparato digestive”. XVII. Barcelona, España: ELSEVIER (2013): 266-269.
6. Villaca G., et al. “Asociación entre la enfermedad de hígado graso no alcohólico y marcadores de la función / de lesiones hepáticas con componentes del síndrome metabólico en la clase III individuos obesos”. Revista da Associacao Medica Brasileira3 (2012): 288-293.
7. Aller R., et al. “Lys656Asn polymorphism of leptin receptor, leptin levels and insulin resistance in patients with nonalcoholic fatty liver disease”. European Review for Medical and Pharmacological Sciences 16 (2012): 335-341.
8. Adams L., et al. “Enfermedad del hígado Graso no alcohólico”. CMAJ: Canadian Medical Association Journal7 (2005): 899-905.
9. Registro de defunciones (2011).
10. Kaser S., et al. “Adiponectin and its receptors in non-alcoholic steatohepatitis”. Gut 54 (2005): 117-121.
11. Domínguez V., et al. “Etiopatogenia, diagnóstico y tratamiento de la enfermedad del hígado graso no alcohólica”. Revista Espanola de Enfermedades Digestivas7 (2013): 409-420.
12. Santos L., et al. “Nonalcoholic fatty liver disease. The new millennium pandemia”. Asoc Colomb Gastroenterol Endosc Dig Coloproctol Hepatol (2010): 373-391.
13. Angulo P. “La enfermedad del hígado graso no alcohólico”. The New England Journal of Medicine 346 (2002): 1221-1231.
14. Sumida Y., et al. “Limitations of liver biopsy and non-invasiv diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis”. Mundial Journal of Gastroenterology2 (2014): 475-485.
15. Lee J and Stanley R. “TC correlación RM” (2008).
16. Hernaez R., et al. “Diagnostic Accuracy and Reliability of Ultrasonography for the Detection of Fatty Liver: A Meta Analysis”. Hepatology 3 (2014): 201.
17. Angulo P. “La enfermedad del hígado graso no alcohólico”. The New England Journal of Medicine 346 (2002): 1221-1231.
18. Saadeh S., et al. “La utilidad de las imágenes radiológicas en la enfermedad de hígado graso no alcohólico”. Gastroenterología 123 (2002): 745-750.
19. Lee J., et al. “Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease (2010).
20. Ratziu LFRP. “Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease”. Alimentary Pharmacology and Therapeutics10 (2014): 1209-1222.
21. Michael Roden SKKK. “Comparison of Liver Fat Indices for the Diagnosis of Hepatic Steatosis and Insulin Resistance”. Plos One (2014).
22. Paul Angulo JC. “Noninvasive Prediction of Hepatic Steatosis”. The American Journal of Gastroenterology (2014): 1415-1416.
23. Younossi Z., et al. “Global epidemiology of nonalcoholic fatty liver disease-Meta- analytic assessment of prevalence, incidence, and outcomes” (2016).
24. Sayiner M., et al. “Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the rest of the world” (2015).